Biohaven Therapeutics Ltd. has divulged compounds targeting TAR DNA-binding protein 43 (TDP43) reported to be useful for the treatment of amyotrophic lateral sclerosis, traumatic encephalopathy, sporadic inclusion body myositis, frontotemporal dementia and Alzheimer's disease.
Nacuity Pharmaceuticals Inc. and Arctic Therapeutics LLC have entered into an exclusive licensing agreement and strategic partnership for the development and commercialization of NPI-001 (N-acetylcysteine amide, NACA) in Iceland for the treatment of hereditary cystatin C amyloid angiopathy (HCCAA).
Coave Therapeutics SA has entered into a collaboration with the Institute of Neurodegenerative Diseases (IMN), a joint research unit associating the University of Bordeaux and the French National Centre of Scientific Research (CNRS), to develop gene therapy programs targeting protein degradation in neurodegenerative disorders.
Age-related diseases have been explained as due in part to the excessive generation and accumulation of waste products like the various insoluble protein aggregates observed in nondividing neurons of Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and Huntington’s disease.
Pharmaxis Ltd. has found new funding to breathe life into a drug that looked like it might sit on the shelf for a while, but now appears to be a good candidate for tackling Parkinson’s and other neurodegenerative diseases.
An investigational drug developed in Cuba for the potential treatment of Alzheimer´s and Parkinson's diseases has moved forward to phase III trials there, where scientists are optimistic about results of previous studies. The candidate, named Neuroepo and branded Neuralcim, was developed by the Center of Molecular Immunology (also known by its Spanish acronym CIM), a state-owned lab in the Caribbean nation.
Aliad Biopharma Co. Ltd. has presented compounds acting as autophagy inducer, mTOR complex 1 (mTORC1) and mTORC2 inhibitors reported to be useful for the treatment of autism spectrum disorders, Alzheimer’s disease, epilepsy, fragile-X syndrome, macrocephaly and tuberous sclerosis.
Marvel Biotechnology Inc. has synthesized purine compounds acting as adenosine A2A receptor (ADORA2A) antagonists reported to be useful for the treatment of cancer, depression, multiple sclerosis, nonalcoholic steatohepatitis (NASH), scleroderma, attention deficit hyperactivity disorder (ADHD), and Parkinson's and Alzheimer's diseases.
China's National Medical Products Administration (NMPA) has cleared CSPC Pharmaceutical Group Limited to conduct clinical trials of TG-103 injection for the treatment of Alzheimer's disease and for the treatment of nonalcoholic steatohepatitis (NASH).
RSS
